Back to News >

Poor solubility is becoming increasingly prevalent in drug pipelines. Infact, across the pharmaceutical industry, about 70 percent of drugs that enter development possess insufficient aqueous solubility for adequate and consistent gastrointestinal absorption.

In a recent article with Drug Development & Delivery, Quotient Sciences, Dr. Jacob discussed how the industries solubility and bioavailability challenges increase for­mulation complexity, raise failure rates, and drive-up development costs. At Quotient Sciences we find solutions to unlocking the potential of each small molecule we work with.

Read more:

External URL: https://www.quotientsciences.com/news/dr-dolly-jacob-solubility-bioavailability-challenge/